Claritev (CTEV) Earnings Date & Reports

Key Takeaways

• Revenue climbed 9.1% year over year to $268.3 million, surpassing consensus estimates of roughly $256 million.
• Net loss narrowed to $61.8 million, with a diluted loss of $3.64 per share, an improvement from the $4.23 loss reported a year earlier.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose 4.4% to $162.0 million, though the adjusted EBITDA margin slipped to 60.4% from 63.1%.
• Management raised full-year 2026 guidance across revenue, adjusted EBITDA, and free cash flow, and introduced a preliminary 2027 revenue target of about $1.1 billion.
• Free cash flow remained negative at -$25.8 million, while unrestricted cash on the balance sheet stood at $10.1 million.
• For deeper context, visit Tickeron to review Major News, Today's Price Move, Price Targets, and Forecast for CTEV.
• To see how AI-driven trading strategies are positioned across the market, explore Trending AI Robots.

Earnings Context and Why It Matters

Claritev Corporation, a healthcare technology, data, and insights company, is in the middle of a multi-year transformation aimed at returning to consistent revenue growth after a period of contraction. Its third-quarter 2026 report matters because it tests whether that growth is broadening beyond payer clients and whether the company can convert accelerating top-line momentum into stronger profitability and cash generation. Investors have been closely watching claims intelligence volumes tied to the No Surprises Act, alongside the company's push into new verticals and AI-enabled workflows. With a heavily leveraged balance sheet and persistent GAAP (Generally Accepted Accounting Principles) losses, the market is equally focused on margins, free cash flow, and the credibility of management's forward guidance.

Reported Results

For the third quarter ended September 30, 2026, Claritev reported revenue of $268.3 million, up 9.1% from $246.0 million in the prior-year period and ahead of consensus estimates near $256 million. Net loss narrowed to $61.8 million, or $3.64 per diluted share, compared with a net loss of $69.8 million, or $4.23 per share, a year earlier.

Adjusted EBITDA increased 4.4% to $162.0 million, but the adjusted EBITDA margin compressed to 60.4% from 63.1%, reflecting increased go-to-market investment and shifting revenue mix. Net cash provided by operating activities was $18.1 million, while free cash flow was negative $25.8 million as capital expenditures rose. The company ended the quarter with $10.1 million in unrestricted cash.

Management also raised its full-year 2026 outlook. Revenue guidance moved to $1.038 billion to $1.043 billion, adjusted EBITDA guidance to $625 million to $630 million, and free cash flow guidance to $10 million to $20 million. The company separately introduced a preliminary 2027 revenue view of at least $1.1 billion, roughly a year ahead of its prior plan.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For those tracking healthcare technology names like Claritev alongside broader industry trends, the AI Screener offers a structured way to narrow the universe and identify candidates that fit specific criteria.

Market Reaction and Investor Sentiment

Claritev shares advanced in the session following the release, with the stock trading higher after closing near $22.71 in the prior session. The positive reaction reflected a third consecutive quarter of raised guidance and a top-line beat that reinforced the company's growth narrative. Still, sentiment heading into the report had been mixed: the stock had pulled back sharply from its post-second-quarter highs, and short interest represented a meaningful portion of the float. The market's focus remains divided between the strengthening revenue and bookings story and concerns around margin compression, thin liquidity, and elevated leverage. The narrowed loss and higher guidance supported the bulls, but the decline in adjusted EBITDA margin and negative free cash flow kept the reaction measured.

Forward Outlook and Key Factors to Monitor

Following this report, investors will be watching whether Claritev can sustain its accelerating revenue growth while stabilizing margins. The company attributed part of the margin squeeze to deliberate go-to-market investment, so evidence that these investments are converting into bookings and revenue will be a key test in the quarters ahead.

Cash flow remains the central concern. Management's raised full-year free cash flow guidance depends on a notably strong fourth quarter, which will need to be validated by actual results rather than projections. With unrestricted cash near $10 million and revolver borrowings rising, the trajectory of free cash flow conversion is likely to matter more to investors than another revenue beat.

Finally, watch the diversification story. More than half of recent bookings came from outside the payer market, and claims intelligence growth has been a primary driver. Sustaining that breadth, delivering on the preliminary 2027 revenue target, and eventually returning payment and revenue integrity segments to growth will be important milestones as the company works to prove the durability of its turnaround.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations